Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of a new treatment regimen
(Chidamide combined with Zimberelimab) in the treatment of patients with metastatic triple
negative breast cancer after the second-line therapy.